# Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status

> **NCT05826483** · PHASE1 · UNKNOWN · sponsor: **Guangzhou Institute of Respiratory Disease** · enrollment: 20 (estimated)

## Conditions studied

- Malignant Tumor of Lung
- Poor Performance Status

## Interventions

- **DRUG:** Almonertinib

## Key facts

- **NCT ID:** NCT05826483
- **Lead sponsor:** Guangzhou Institute of Respiratory Disease
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-01
- **Primary completion:** 2024-12-28
- **Final completion:** 2024-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05826483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05826483, "Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05826483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*